Prasugrel versus clopidogrel for acute coronary syndromes without revascularization (2012)
- Authors:
- Roe, Matthew T
- Armstrong, Paul W
- Fox, Keith A. A
- White, Harvey
- Prabhakaran, Dorairaj
- Goodman, Shaun G
- Cornel, Jan H
- Bhatt, Deepak L
- Clemmensen, Peter
- Martinez, Felipe
- Ardissino, Diego
- Nicolau, Jose Carlos
- Boden, William E
- Gurbel, Paul A
- Ruzyllo, Witold
- Dalby, Anthony J
- McGuire, Darren K
- Leiva-Pons, Jose L
- Parkhomenko, Alexander
- Gottlieb, Shmuel
- Topacio, Gracita O
- Hamm, Christian
- Pavlides, Gregory
- Goudev, Assen R
- Oto, Ali
- Tseng, Chuen-Den
- Merkely, Bela
- Gasparovic, Vladimir
- Corbalan, Ramon
- Cinteză, Mircea
- McLendon, R. Craig
- Winters, Kenneth J
- Brown, Eileen B
- Lokhnygina, Yuliya
- Aylward, Philip E
- Huber, Kurt
- Hochman, Judith S
- Ohman, E. Magnus
- Marin Neto, Jose Antonio
- USP affiliated authors: MARIN NETO, JOSE ANTONIO - FMRP ; NICOLAU, JOSÉ CARLOS - FM
- Unidades: FMRP; FM
- DOI: 10.1056/NEJMoa1205512
- Assunto: REVASCULARIZAÇÃO MIOCÁRDICA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: The New England Journal of Medicine
- ISSN: 0028-4793
- Volume/Número/Paginação/Ano: v. 367, n. 14, p. 1297-1309, 2012
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
ROE, Matthew T et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. The New England Journal of Medicine, v. 367, n. 14, p. 1297-1309, 2012Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1205512. Acesso em: 18 abr. 2024. -
APA
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H., Prabhakaran, D., Goodman, S. G., et al. (2012). Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. The New England Journal of Medicine, 367( 14), 1297-1309. doi:10.1056/NEJMoa1205512 -
NLM
Roe MT, Armstrong PW, Fox KAA, White H, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng C-D, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM, Marin Neto JA. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization [Internet]. The New England Journal of Medicine. 2012 ; 367( 14): 1297-1309.[citado 2024 abr. 18 ] Available from: https://doi.org/10.1056/NEJMoa1205512 -
Vancouver
Roe MT, Armstrong PW, Fox KAA, White H, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng C-D, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM, Marin Neto JA. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization [Internet]. The New England Journal of Medicine. 2012 ; 367( 14): 1297-1309.[citado 2024 abr. 18 ] Available from: https://doi.org/10.1056/NEJMoa1205512 - Long-term use of ticagrelor in patients with prior myocardial infarction
- Resumo Executivo: Diretrizes da SBC sobre Angina Instável e Infarto Agudo do Miocárdio Sem Supradesnível do Segmento ST
- Vorapaxar in the secondary prevention of atherothrombotic events
- Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
Informações sobre o DOI: 10.1056/NEJMoa1205512 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
